Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short-term Investments: 2023-2024

Historic Short-term Investments for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $9.1 million.

  • BioLineRx's Short-term Investments fell 26.83% to $21.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $21.0 million, marking a year-over-year decrease of 26.83%. This contributed to the annual value of $9.1 million for FY2024, which is 76.44% down from last year.
  • According to the latest figures from FY2024, BioLineRx's Short-term Investments is $9.1 million, which was down 76.44% from $38.7 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Short-term Investments registered a high of $38.7 million during FY2023, and its lowest value of $9.1 million during FY2024.
  • Moreover, its 2-year median value for Short-term Investments was $23.9 million (2023), whereas its average is $23.9 million.
  • Data for BioLineRx's Short-term Investments shows a maximum YoY tumbled of 76.44% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Short-term Investments (Yearly) stood at $38.7 million in 2023, then slumped by 76.44% to $9.1 million in 2024.